personalised Diabetes Management using lOw cost Needle free multiple biomarkers...
personalised Diabetes Management using lOw cost Needle free multiple biomarkers monitoring Device
"""Diabetes is the #1 health challenge of the 21st century. Continuous Glucose Monitoring or CGM ($1.25B market in 2016, growing 29%/yr) is today’s cornerstone of diabetes self-management and the most effective solution to reduce...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
PDC2021-121470-C21
PREDICCION DE GLUCOSA SIN INTERVENCION DEL USUARIO PARA EL A...
69K€
Cerrado
PREVENTDIABETES
The world’s first needle-free continuous glucose monitor to...
7M€
Cerrado
INSULYNC
INSULYNC Changing the way diabetes is treated
71K€
Cerrado
Elektrosens
Wearable Sweat based painless and continuous glucose monitor...
71K€
Cerrado
SPIDIMAN
Single Port Insulin Infusion for Improved Diabetes Managemen...
6M€
Cerrado
PID2019-107722RB-C21
SOLUCIONES A MEDIDA DEL PACIENTE PARA EL CONTROL DE GLUCOSA...
220K€
Cerrado
Información proyecto DiaMOND
Duración del proyecto: 37 meses
Fecha Inicio: 2018-05-10
Fecha Fin: 2021-06-30
Líder del proyecto
INDIGO DIABETES
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
5M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
"""Diabetes is the #1 health challenge of the 21st century. Continuous Glucose Monitoring or CGM ($1.25B market in 2016, growing 29%/yr) is today’s cornerstone of diabetes self-management and the most effective solution to reduce the economic and societal burden of diabetes. But the shortcomings of current CGMs hinder their wider adoption: high cost, unsatisfactory predictability of severe events, and poor user comfort. The DiaMOND project will remove these barriers by bringing needle-free, low-cost Continuous Diabetes Monitoring to market. DiaMOND is specifically geared at extending Indigo’s current CGM with reliable severe clinical event prediction and a great user experience; demonstrating the reliability in a first-in-man trial; creating market acceptance by involving Key Opinion Leaders; and obtaining reimbursement. Indigo will be ready for a large pivotal clinical study and CE marking after completing the DiaMOND project. DiaMOND will accelerate Indigo’s CDM market access by 2-3 years."""